造影剤市場規模、シェア、動向、2031年までの世界予測

世界の造影剤市場は、2025年の76億5,000万米ドルから2031年には120億8,000万米ドルに成長し、、2026年から2031年までの年平均成長率（CAGR）は7.9%に達するとMarketsandMarketsでは予測しています。

造影剤市場は主に、造影剤製剤の革新と、画像診断の精度を高め、精密診断に対する高まる需要に応える標的型および活性化型造影剤の開発によって牽引されています。さらに、診断画像サービスの拡大や枠組み協定の締結といった医療イニシアチブへの政府投資は、高度な画像診断オプションへのアクセスを支援しています。加えて、がんや心血管疾患などの慢性疾患の罹患率の上昇に伴い、早期発見、モニタリング、治療計画のために造影画像診断が必要となっています。

調査概要

本レポートは、造影剤市場を種類、適応症、投与方法、投与経路、用途、エンドユーザー、地域別に分析しています。また、市場成長に影響を与える要因、市場における様々な機会と課題、そして市場リーダーの競争環境についても詳細に解説しています。さらに、成長トレンドに基づいたマイクロマーケット分析も行っています。主要5地域（および各地域内の各国）における市場セグメントの収益予測も掲載しています。

本レポートを購入する理由

本レポートは、市場リーダーや新規参入企業に対し、造影剤市場全体およびそのサブセグメントの収益に関する最も正確な予測情報を提供します。関係者は、本レポートを通じて競争環境を理解し、より深い洞察を得ることで、自社の事業をより効果的に位置づけ、適切な市場参入戦略を策定することができます。また、市場の動向を把握し、主要な推進要因、阻害要因、課題、機会に関する洞察を得ることも可能です。

本レポートでは、以下のポイントについて考察します。

造影剤市場の成長に影響を与える主要な推進要因（造影剤を用いたスキャン件数の増加、造影剤製剤の進歩、精密診断のための標的型および活性化型造影剤の開発の進展、診断画像検査の拡大を支援する政府投資およびNHS（国民保健サービス）の枠組み協定）、阻害要因（副作用のリスク、画像検査の高コスト、造影剤の循環時間と安定性の制限、ガドリニウム系造影剤の環境残留性）、機会（インターベンショナルラジオロジーおよび画像誘導下手技の成長、マイクロバブルおよび超音波造影剤の開発、小児腹部画像検査における造影超音波検査（CEUS）の応用拡大）、および課題（放射線科における人材不足、サプライチェーンの脆弱性、新規およびマルチモーダル造影剤の複雑な規制承認経路）の分析

• 製品開発／イノベーション：今後の製品に関する詳細な考察造影剤市場における技術、研究開発活動、新製品・新サービスの発売状況
• 市場開発：収益性の高い市場に関する包括的な情報 ― 本レポートは、様々な地域における造影剤市場を分析します。
• 市場の多様化：造影剤市場における新製品・サービス、未開拓地域、最新動向、投資に関する詳細な情報
• 競合分析：Bracco Imaging S.p.A.（イタリア）、Bayer AG（ドイツ）、Guerbet（米国）、GE HealthCare（米国）などの主要企業の市場シェア、成長戦略、サービス提供内容を詳細に分析します。

Report Description

The global contrast media market is projected to reach USD 12.08 billion by 2031 from USD 7.65 billion in 2025, at a CAGR of 7.9% from 2026 to 2031. The contrast media market is mainly driven by innovation in contrast agent formulations and the development of targeted and activatable contrast agents, which enhance the accuracy of imaging studies and meet the increasing demand for precise diagnostics. Additionally, government investments in healthcare initiatives, such as expanding diagnostic imaging services and establishing framework agreements, support access to advanced imaging options. Moreover, the rising prevalence of chronic diseases like cancer and cardiovascular conditions necessitates contrast imaging studies for early detection, monitoring, and treatment planning.

“The cardiovascular disease segment held the largest share of the market in 2026.”

By indication, the contrast media market is segmented into cardiovascular disease, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. The cardiovascular disease segment held the largest market share in 2026, driven by the high volume of diagnostic and interventional procedures such as coronary angiography, CT angiography, and cardiac catheterization. The increasing prevalence of heart disorders worldwide has made contrast-enhanced imaging a standard practice for accurate diagnosis and treatment planning. Additionally, the urgent need for real-time visualization of vessels during cardiac surgery has sustained a steady demand for contrast agents. Furthermore, the introduction of advanced imaging technology in cardiology is a key driver of this segment’s dominance.

“The interventional cardiology segment is projected to register the highest CAGR during the forecast period.”

By application, the contrast media market is segmented into radiology, interventional radiology, and interventional cardiology. The interventional cardiology segment is expected to have the highest CAGR from 2026 to 2031, driven by the rapid growth of minimally invasive cardiac procedures, including angioplasty, stent placement, and catheter-based interventions. The number of procedures is increasing because of a rise in coronary artery disease and lifestyle-related cardiac disorders. Additionally, the development of catheterization labs and imaging-guided technologies has led to greater use of contrast agents in cardiac interventions. Furthermore, the segment is being further supported by patients’ increasing preference for quick recovery and shorter hospital stays.

“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”

The rapid development of healthcare infrastructure in nations such as China, India, and Japan is driving growth in the contrast media market in the Asia Pacific region. Access to contrast-enhanced procedures is becoming better due to rising healthcare costs and the growing use of sophisticated diagnostic imaging systems. Imaging volumes are also being driven throughout the region by the rising prevalence of chronic illnesses and the growth of medical tourism. Additionally, the market is expanding faster due to the government’s strong support for hospital modernization and early diagnosis.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the contrast media market are Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (US), Lantheus Medical Imaging (US), GE HealthCare (US), Unijules Life Sciences Ltd. (India), J.B. Chemicals & Pharmaceuticals Limited (India), Sanochemia Pharmazeutika GmbH (Germany), Taejoon Pharm Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Beijing Beilu Pharmaceutical Co., Ltd. (China), and Livealth Biopharma Pvt. Ltd. (India) among others.

Research Coverage

This report studies the contrast media market based on type, indication, modality, route of administration, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets by growth trends. It forecasts market segment revenue across five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help market leaders/new entrants with information on the closest approximations of revenue for the overall contrast media market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides insights into key drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (Rising number of contrast- mediated scan, Advancements in contrast agent formulations, increasing development of targeted and activatable contrast agents for precision diagnostics  and Government Investment and NHS Framework Agreements Supporting Diagnostic Imaging Expansion), restraints (Risk of Adverse Reactions, High Cost of Imaging Procedures, Limited circulation time and stability of contrast agents, environmental persistence of gadolinium-based contrast agents), opportunities (Growth of Interventional Radiology and Image-Guided Procedures, Development of Microbubble and Ultrasound Contrast Agents, Expansion of Contrast-Enhancced Ultrasound (CEUS) Applications in Pediatric Abdominal Imaging), and challenges (Workforce Shortages in Radiology, Supply Chain Vulnerabilities, Complex Regulatory Approval Pathways for Novel and Multimodal Contrast Agents) influencing the growth of the contrast media market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the contrast media market
• Market Development: Comprehensive information about lucrative markets–the report analyses the contrast media market across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the contrast media market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (US), GE HealthCare (US), and others.

Table of Contents

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 25
1.3.2 INCLUSIONS & EXCLUSIONS 26
1.3.3 YEARS CONSIDERED 26
1.3.4 CURRENCY CONSIDERED 27
1.4 MARKET STAKEHOLDERS 27
1.5 SUMMARY OF CHANGES 27
2 EXECUTIVE SUMMARY 29
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 29
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 31
2.3 DISRUPTIVE TRENDS IN CONTRAST MEDIA MARKET 32
2.4 HIGH GROWTH SEGMENTS 33
3 PREMIUM INSIGHTS 35
3.1 CONTRAST MEDIA MARKET OVERVIEW 35
3.2 CONTRAST MEDIA MARKET, BY REGION 36
3.3 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY AND END USER 37
3.4 GEOGRAPHIC SNAPSHOT OF CONTRAST MEDIA MARKET 38
4 MARKET OVERVIEW 39
4.1 INTRODUCTION 39
4.2 MARKET DYNAMICS 39
4.2.1 DRIVERS 41
4.2.1.1 Advancements in contrast agent formulations 41
4.2.1.2 Precision Diagnostics Enabled by Targeted and Activatable Contrast Agents 42
4.2.1.3 Government Investments and Healthcare Procurement Initiatives 42
4.2.1.4 Rising number of contrast-mediated scans 43
4.2.2 RESTRAINTS 43
4.2.2.1 Limited Circulation Time and Stability of Certain Contrast Agents 43
4.2.2.2 Environmental persistence of gadolinium-based contrast agents 43
4.2.3 OPPORTUNITIES 44
4.2.3.1 Expansion of Multimodal Imaging Technologies 44
4.2.3.2 Expansion of Contrast-enhanced ultrasound (CEUS) applications in pediatric imaging 45
4.2.3.3 Increasing demand for low-dose, high-relaxivity contrast agents for neonates and infants 46
4.2.4 CHALLENGES 46
4.2.4.1 Safety and toxicity concerns associated with gadolinium and nanoparticle-based contrast agents 46
4.2.4.2 Complex regulatory approval pathways for novel and multimodal contrast agents 47
4.2.4.3 Complexity in scalable synthesis and standardization of nanoparticle-based contrast agents 47
4.3 UNMET NEEDS 47
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 48
5 INDUSTRY TRENDS 50
5.1 PORTER’S FIVE FORCES ANALYSIS 50
5.2 MACROECONOMIC INDICATORS 52
5.2.1 INTRODUCTION 52
5.2.2 HEALTHCARE EXPENDITURE AND INFRASTRUCTURE OUTLOOK 52
5.2.2.1 Macroeconomic outlook for NORTH AMERICA 52
5.2.3 MACROECONOMIC OUTLOOK FOR EUROPE 52
5.2.4 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 53
5.2.5 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 53
5.2.6 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 54
5.3 SUPPLY CHAIN ANALYSIS 54
5.4 ECOSYSTEM ANALYSIS 55
5.5 PRICING ANALYSIS 57
5.5.1 AVERAGE SELLING PRICE TREND, BY REGION 57
5.5.2 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER 60
5.5.3 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS,
BY KEY PLAYER, 2024 60
5.6 TRADE DATA ANALYSIS 61
5.6.1 IMPORT DATA (HS CODE 300630) 61
5.6.2 EXPORT DATA (HS CODE 300630) 61
5.7 KEY CONFERENCES & EVENTS, 2026–2027 62
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
5.9 INVESTMENT & FUNDING SCENARIO 64
5.10 CASE STUDY ANALYSIS 65
5.10.1 CASE STUDY 1: MACROCYCLIC CONTRAST AGENTS FOR IMPROVED
MRI SAFETY 65
5.10.2 CASE STUDY 2: IODINATED CONTRAST MEDIA OPTIMIZATION IN CT IMAGING 66
5.10.3 CASE STUDY 3: LOW-DOSE MRI CONTRAST AGENT FOR PEDIATRIC
MRI IMAGING 66
5.11 IMPACT OF 2025 US TARIFF― CONTRAST MEDIA MARKET 66
5.11.1 INTRODUCTION 66
5.11.2 KEY TARIFF RATES 67
5.11.3 PRICE IMPACT ANALYSIS 67
5.11.4 IMPACT ON COUNTRY/REGION 68
5.11.5 IMPACT ON END USERS 69
6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 70
6.1 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 70
6.1.1 BUYING CRITERIA 71
6.1.2 DECISION-MAKING PROCESS 72
6.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 73
6.3 UNMET NEEDS FROM END USERS 73
6.3.1 UNMET NEEDS FROM END USERS 75
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS,
AND AI ADOPTION 76
7.1 KEY TECHNOLOGIES 76
7.1.1 CONTRAST-ENHANCED ULTRASOUND (CEUS) ADVANCEMENTS 76
7.1.1.1 Targeted and molecular contrast agents 76
7.1.1.2 Advanced gadolinium-based agents and hyperpolarized techniques 77
7.1.2 COMPLEMENTARY TECHNOLOGIES 77
7.1.2.1 Automated contrast injector systems 77
7.2 PATENT ANALYSIS 78
7.2.1 CONTRAST MEDIA MARKET: LIST OF PATENTS 79
7.3 FUTURE APPLICATIONS 79
7.4 IMPACT OF AI/GEN AI ON CONTRAST MEDIA MARKET 80
7.4.1 TOP USE CASES AND MARKET POTENTIAL 80
7.4.2 BEST PRACTICES IN CONTRAST MEDIA. 81
7.4.3 CASE STUDIES OF AI IMPLEMENTATION IN CONTRAST MEDIA MARKET 82
7.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT
ON MARKET PLAYERS 82
7.4.5 CLIENT READINESS TO ADOPT GENERATIVE AI IN CONTRAST MEDIA MARKET 83
7.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 84
8 CONTRAST MEDIA MARKET, BY TYPE 85
8.1 INTRODUCTION 86
8.2 IODINATED CONTRAST MEDIA 86
8.2.1 RISING ADOPTION OF CT IMAGING INCREASES DEMAND 86
8.3 GADOLINIUM-BASED CONTRAST MEDIA 87
8.3.1 SAFETY CONCERNS ASSOCIATED WITH GADOLINIUM-BASED CONTRAST AGENTS RESTRAIN MARKET GROWTH 87
8.4 MICROBUBBLE CONTRAST MEDIA 89
8.4.1 GROWING PHYSICIAN PREFERENCE FOR CONTRAST-ENHANCED ULTRASOUND DRIVES ADOPTION 89

8.5 BARIUM-BASED CONTRAST MEDIA 90
8.5.1 ADVERSE EFFECTS ASSOCIATED WITH BARIUM SULFATE CONTRAST MEDIA LIMIT CLINICAL USAGE 90
9 CONTRAST MEDIA MARKET, BY FORM 92
9.1 INTRODUCTION 93
9.2 LIQUID 93
9.2.1 CONVENIENCE OF USE IN HOSPITALS AND DIAGNOSTIC CENTERS
TO DRIVE MARKET GROWTH 93
9.3 POWDER 94
9.3.1 CONVENIENT HANDLING, STORAGE, AND TRANSPORTATION DRIVES INCREASED ADOPTION 94
9.4 OTHER FORMS 95
10 CONTRAST MEDIA MARKET, BY MODALITY 97
10.1 INTRODUCTION 98
10.2 X-RAY 98
10.2.1 DEVELOPMENT OF SAFER, LOW-CONCENTRATION CONTRAST AGENTS
FOR X-RAY – KEY OPPORTUNITY 98
10.3 CT 100
10.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET 100
10.4 MRI 101
10.4.1 INCREASING FOCUS ON NEXT-GENERATION GADOLINIUM-BASED CONTRAST AGENTS TO ENHANCE SAFETY AND IMAGING PERFORMANCE 101
10.5 ULTRASOUND 103
10.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY – KEY FACTORS DRIVING MARKET GROWTH 103
11 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 105
11.1 INTRODUCTION 106
11.2 INTRAVASCULAR ROUTE 106
11.2.1 INCREASING CLINICAL RELIANCE FOR ENHANCED DIAGNOSTIC IMAGING AND TREATMENT OUTCOMES TO DRIVE SEGMENT 106
11.2.1.1 Intravenous (IV) route 107
11.2.1.2 Intra-arterial (IA) route 108
11.3 ORAL ROUTE 109
11.3.1 ENHANCING GASTROINTESTINAL VISUALIZATION WITH ORAL CONTRAST AGENTS IN DIAGNOSTIC IMAGING 109
11.4 RECTAL ROUTE 111
11.4.1 RISING DEMAND FOR ACCURATE POST-SURGICAL COMPLICATION DETECTION TO DRIVE ADOPTION 111
11.5 OTHER ROUTES 112

12 CONTRAST MEDIA MARKET, BY INDICATION 114
12.1 INTRODUCTION 115
12.2 CARDIOVASCULAR DISEASE 115
12.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET 115
12.3 CANCER 116
12.3.1 ADVANCED ONCOLOGIC DIAGNOSTICS THROUGH CONTRAST-ENHANCED ULTRASOUND IMAGING TO BOOST SEGMENT 116
12.4 GASTROINTESTINAL DISORDERS 117
12.4.1 EXPANDING ROLE OF CEUS IN PEDIATRIC GASTROINTESTINAL DISORDERS AND NEONATAL IMAGING TO PROPEL GROWTH 117
12.5 MUSCULOSKELETAL DISORDERS 118
12.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH 118
12.6 NEUROLOGICAL DISORDERS 120
12.6.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS DRIVES DEMAND 120
12.7 NEPHROLOGICAL DISORDERS 121
12.7.1 RISING PREVALENCE OF END-STAGE RENAL DISEASE TO DRIVE DEMAND 121
13 CONTRAST MEDIA MARKET, BY APPLICATION 123
13.1 INTRODUCTION 124
13.2 RADIOLOGY 124
13.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET 124
13.3 INTERVENTIONAL RADIOLOGY 125
13.3.1 RISING ADOPTION OF MINIMALLY INVASIVE INTERVENTIONS TO DRIVE MARKET 125
13.4 INTERVENTIONAL CARDIOLOGY 126
13.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET 126
14 CONTRAST MEDIA MARKET, BY END USER 128
14.1 INTRODUCTION 129
14.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 129
14.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET 129
14.3 DIAGNOSTIC IMAGING CENTERS 131
14.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET 131
15 CONTRAST MEDIA MARKET, BY REGION 133
15.1 INTRODUCTION 134
15.2 NORTH AMERICA 134
15.2.1 US 139
15.2.1.1 Rising incidence of chronic diseases to drive market 139
15.2.2 CANADA 140
15.2.2.1 Growth influenced by supply expansion and increasing market competition 140
15.3 EUROPE 141
15.3.1 GERMANY 144
15.3.1.1 Presence of well-established players to support market growth 144
15.3.2 FRANCE 145
15.3.2.1 Growth supported by high imaging utilization and expanding clinical applications 145
15.3.3 UK 146
15.3.3.1 Innovation in next-generation MRI contrast agents to drive growth 146
15.3.4 ITALY 148
15.3.4.1 Growth driven by innovation in ultrasound contrast agents and product expansion 148
15.3.5 SPAIN 149
15.3.5.1 Shift toward safer and cost-efficient low-osmolar contrast agents in CT imaging to boost market 149
15.3.6 REST OF EUROPE 149
15.4 ASIA PACIFIC 150
15.4.1 CHINA 154
15.4.1.1 Strong domestic capabilities and strategic supply chain position drive market growth 154
15.4.2 JAPAN 155
15.4.2.1 Advanced imaging infrastructure and strategic industry expansion to drive demand 155
15.4.3 INDIA 156
15.4.3.1 Expanding domestic manufacturing and increasing imaging demand to propel market growth 156
15.4.4 AUSTRALIA 157
15.4.5 SOUTH KOREA 158
15.4.5.1 AI-driven imaging optimization and rising early-onset cancer burden reshaping demand 158
15.4.6 REST OF ASIA PACIFIC 159
15.4.7 LATIN AMERICA 160
15.4.7.1 Cost-sensitive procurement and rising CT imaging volumes drive contrast media utilization 160
15.4.8 BRAZIL 164
15.4.8.1 Rising disease burden drives demand amid safety and access challenges 164
15.4.9 MEXICO 165
15.4.9.1 Rising CKD burden, low healthcare spending, and environmental concerns influence contrast media utilization 165
15.4.10 REST OF LATIN AMERICA 166
15.4.10.1 Fragmented access, import dependence, and public–private imbalance shaping contrast media utilization 166
15.4.11 MIDDLE EAST & AFRICA 166
15.4.11.1 High burden of chronic diseases to drive market 166
15.4.12 GCC COUNTRIES 170
15.4.12.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market 170
15.4.13 REST OF MIDDLE EAST & AFRICA 171
15.4.13.1 Import dependence and unbalanced imaging access driving selective contrast media utilization 171
16 COMPETITIVE LANDSCAPE 173
16.1 INTRODUCTION 173
16.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN 173
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
CONTRAST MEDIA MARKET 174
16.3 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET 2021–2025 176
16.4 MARKET SHARE ANALYSIS, 2024 177
16.4.1 MARKET RANKING OF KEY PLAYERS, 2024 179
16.5 COMPANY VALUATION & FINANCIAL METRICS 179
16.5.1 FINANCIAL METRICS 179
16.5.2 COMPANY VALUATION 180
16.6 BRAND/PRODUCT COMPARISON 181
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 182
16.7.1 STARS 182
16.7.2 PERVASIVE PLAYERS 182
16.7.3 EMERGING LEADERS 182
16.7.4 PARTICIPANTS 182
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 184
16.7.5.1 Company footprint 184
16.7.5.2 Region footprint 185
16.7.5.3 Product type footprint 186
16.7.5.4 MODALITY FOOTPRINT 187
16.7.5.5 ROUTE OF ADMINISTRATION FOOTPRINT 188
16.7.5.6 INDICATION FOOTPRINT 189
16.7.5.7 END USER FOOTPRINT 190
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 191
16.8.1 PROGRESSIVE COMPANIES 191
16.8.2 RESPONSIVE COMPANIES 191
16.8.3 DYNAMIC COMPANIES 191
16.8.4 STARTING BLOCKS 191
16.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025 193
16.8.5.1 CONTRAST MEDIA MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMEs 194
16.9 COMPETITIVE SCENARIO 195
16.9.1 PRODUCT LAUNCHES & APPROVALS 195
16.9.2 DEALS 196
16.9.3 EXPANSIONS 196
17 COMPANY PROFILES 197
17.1 KEY PLAYERS 197
17.1.1 GE HEALTHCARE 197
17.1.1.1 Business overview 197
17.1.1.2 Products offered 199
17.1.1.3 Recent developments 199
17.1.1.3.1 Product launches 199
17.1.1.4 MnM view 200
17.1.1.4.1 Key strengths 200
17.1.1.4.2 Strategic choices 200
17.1.1.4.3 Weaknesses & competitive threats 200
17.1.2 BRACCO IMAGING 201
17.1.2.1 Business overview 201
17.1.2.2 Products offered 201
17.1.2.3 Recent developments 203
17.1.2.3.1 Product launches 203
17.1.2.3.2 Deals 203
17.1.2.4 MnM view 204
17.1.2.4.1 Key strengths 204
17.1.2.4.2 Strategic choices 204
17.1.2.4.3 Weaknesses & competitive threats 204
17.1.3 BAYER AG 205
17.1.3.1 Business overview 205
17.1.3.2 Products offered 206
17.1.3.3 Recent developments 207
17.1.3.3.1 Expansions 207
17.1.3.4 MnM view 207
17.1.3.4.1 Key strengths 207
17.1.3.4.2 Strategic choices 207
17.1.3.4.3 Weaknesses & competitive threats 208
17.1.4 GUERBET 209
17.1.4.1 Business overview 209
17.1.4.2 Products offered 210
17.1.4.3 Recent developments 211
17.1.4.3.1 Product approvals 211
17.1.4.4 MnM view 211
17.1.4.4.1 Key strengths 211
17.1.4.4.2 Strategic choices 212
17.1.4.4.3 Weaknesses & competitive threats 212

17.1.5 LANTHEUS HOLDINGS, INC. 213
17.1.5.1 Business overview 213
17.1.5.2 Products offered 214
17.1.5.3 MnM view 214
17.1.5.3.1 Key strengths 214
17.1.5.3.2 Strategic choices 215
17.1.5.3.3 Weaknesses & competitive threats 215
17.1.6 UNIJULES LIFE SCIENCES LTD. 216
17.1.6.1 Business overview 216
17.1.6.2 Products offered 217
17.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED 218
17.1.7.1 Business overview 218
17.1.7.2 Products offered 219
17.1.8 SANOCHEMIA PHARMAZEUTIKA 221
17.1.8.1 Business overview 221
17.1.8.2 Products offered 222
17.1.9 TAEJOON PHARM CO., LTD. 223
17.1.9.1 Business overview 223
17.1.9.2 Products offered 223
17.1.10 JODAS EXPOIM 224
17.1.10.1 Business overview 224
17.1.10.2 Products offered 225
17.1.11 IMAX DIAGNOSTIC IMAGING LIMITED 226
17.1.11.1 Business overview 226
17.1.11.2 Products offered 226
17.1.11.3 Pipeline products 227
17.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP 228
17.1.12.1 Business overview 228
17.1.12.2 Pipeline products 229
17.1.13 LIVEALTH 230
17.1.13.1 Business overview 230
17.1.13.2 Products offered 230
17.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD. 232
17.1.14.1 Business overview 232
17.1.14.2 Products offered 232
17.1.14.3 Recent developments 233
17.2 OTHER PLAYERS 235
17.2.1 ARCO LIFESCIENCES (I) PVT. LTD. 235
17.2.2 STANEX DRUGS & CHEMICALS PVT. LTD. 236
17.2.3 ONKO İLAÇ SAN. VE TIC. A.Ş. 237
17.2.4 FRESENIUS KABI 238
17.2.5 BIEM ILAC SAN. VE 239
17.2.6 ADVACARE PHARMA 240
17.2.7 FUJIFILM WAKO PURE CHEMICAL CORPORATION 241
17.2.8 UNISPIRE BIOPHARMA PRIVATE LIMITED 242
17.2.9 TRIVITRON HEALTHCARE 242
17.2.10 NANOPET PHARMA GMBH 243
18 RESEARCH METHODOLOGY 244
18.1 RESEARCH DATA 244
18.2 RESEARCH DESIGN 245
18.2.1 SECONDARY RESEARCH 245
18.2.1.1 Objectives of secondary research 246
18.2.1.2 Key data from secondary sources 247
18.2.2 PRIMARY RESEARCH 247
18.2.2.1 Objectives of primary research 248
18.2.2.2 Key industry insights 249
18.3 MARKET SIZE ESTIMATION METHODOLOGY 250
18.3.1 BOTTOM-UP APPROACH 251
18.3.1.1 Approach 1: Company revenue estimation approach 251
18.3.1.2 Approach 4: Primary interviews 252
18.3.2 TOP-DOWN APPROACH 252
18.4 MARKET BREAKDOWN AND DATA TRIANGULATION 255
18.5 MARKET SHARE ASSESSMENT 255
18.6 RESEARCH ASSUMPTIONS 256
18.7 RESEARCH LIMITATIONS 256
18.8 RISK ASSESSMENT 257
19 APPENDIX 258
19.1 DISCUSSION GUIDE 258
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 263
19.3 CUSTOMIZATION OPTIONS 265
19.4 RELATED REPORTS 265
19.5 AUTHOR DETAILS 266

LIST OF TABLES

TABLE 1 CONTRAST MEDIA MARKET: INCLUSIONS AND EXCLUSIONS 26
TABLE 2 CONTRAST MEDIA MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 40
TABLE 3 KEY TECHNOLOGICAL ADVANCEMENTS IN CONTRAST AGENT FORMULATIONS AND THEIR CLINICAL BENEFITS 41
TABLE 4 EMERGING TARGETED AND ACTIVATABLE CONTRAST AGENTS SUPPORTING PRECISION DIAGNOSTICS 42
TABLE 5 EMERGING AND CLINICAL APPLICATIONS OF CONTRAST-ENHANCED ULTRASOUND (CEUS) IN PEDIATRIC ABDOMINAL IMAGING 45
TABLE 6 CONTRAST AGENT MARKET: UNMET NEEDS 47
TABLE 7 STRATEGIC MOVES BY TIER 1, TIER 2, AND TIER 3 PLAYERS IN
CONTRAST MEDIA MARKET 48
TABLE 8 CONTRAST MEDIA MARKET: PORTER’S FIVE FORCES 50
TABLE 9 NORTH AMERICA: MACROECONOMIC OUTLOOK 52
TABLE 10 EUROPE: MACROECONOMIC OUTLOOK 53
TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 53
TABLE 12 LATIN AMERICA: MACROECONOMIC OUTLOOK 54
TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 54
TABLE 14 CONTRAST MEDIA MARKET: ROLE OF ECOSYSTEM 56
TABLE 15 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCT TYPES,
BY REGION, 2024–2026(USD) 59
TABLE 16 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS,
BY KEY PLAYER, (USD) 60
TABLE 17 IMPORT DATA FOR HS CODE 300630, BY COUNTRY,
2021–2025 (USD THOUSAND) 61
TABLE 18 EXPORT DATA FOR HS CODE 300630 BY COUNTRY, 2021–2025 (USD THOUSAND) 61
TABLE 19 CONTRAST MEDIA MARKET: KEY CONFERENCES & EVENTS (2026–2027) 62
TABLE 20 CONTRAST MEDIA APPLICATION IN MRI SAFETY AND STABILITY 65
TABLE 21 CONTRAST MEDIA APPLICATION IN CT IMAGING OPTIMIZATION 66
TABLE 22 CONTRAST MEDIA APPLICATION IN PEDIATRIC MRI IMAGING 66
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 67
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTRAST
MEDIA MARKET, BY PRODUCT 71
TABLE 25 KEY BUYING CRITERIA FOR CONTRAST MEDIA MARKET, BY END USER 72
TABLE 26 CONTRAST MEDIA MARKET: UNMET NEED ANALYSIS 74
TABLE 27 KEY AGENTS USED IN CONTRAST-ENHANCED ULTRASOUND (CEUS) 76
TABLE 28 CONTRAST MEDIA MARKET: KEY PATENTS, 2016–2020 79
TABLE 29 KEY COMPANIES IMPLEMENTING AI IN CONTRAST MEDIA ECOSYSTEM 82
TABLE 30 CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 86
TABLE 31 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 87
TABLE 32 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 88
TABLE 33 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 90
TABLE 34 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 91
TABLE 35 CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 93
TABLE 36 LIQUID CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 94
TABLE 37 POWDER CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 95
TABLE 38 OTHER FORMS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 96
TABLE 39 CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 98
TABLE 40 ENGLAND: COUNT OF X-RAY IMAGING ACTIVITY ON NHS PATIENTS,
MAY 2023–MAY 2024 99
TABLE 41 X-RAY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 99
TABLE 42 ENGLAND: COUNT OF CT IMAGING ACTIVITY ON NHS PATIENTS,
MAY 2023–MAY 2024 100
TABLE 43 CT: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 101
TABLE 44 ENGLAND: COUNT OF MRI IMAGING ACTIVITY ON NHS PATIENTS,
MAY 2023–MAY 2024 102
TABLE 45 MRI: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 102
TABLE 46 ENGLAND: COUNT OF ULTRASOUND IMAGING ACTIVITY ON NHS PATIENTS,
MAY 2023–MAY 2024 104
TABLE 47 ULTRASOUND: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 104
TABLE 48 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 106
TABLE 49 INTRAVASCULAR ROUTE: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 107
TABLE 50 IV ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 108
TABLE 51 IA ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 109
TABLE 52 TYPES OF ORAL CT CONTRAST AGENTS, INCLUDING AGENTS CURRENTLY AVAILABLE AND AGENTS UNDER DEVELOPMENT 110
TABLE 53 ORAL ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 111
TABLE 54 RECTAL ROUTE: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 112
TABLE 55 OTHER ROUTES: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 113
TABLE 56 CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 115
TABLE 57 CARDIOVASCULAR DISEASE: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 116
TABLE 58 CANCER: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 117
TABLE 59 GASTROINTESTINAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 60 MUSCULOSKELETAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 119
TABLE 61 NEUROLOGICAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 121
TABLE 62 NEPHROLOGICAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 122
TABLE 63 CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 124
TABLE 64 RADIOLOGY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 65 INTERVENTIONAL RADIOLOGY: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 66 INTERVENTIONAL CARDIOLOGY: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 67 CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 129
TABLE 68 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 69 DIAGNOSTIC IMAGING CENTERS: CONTRAST MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 70 CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 71 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 72 NORTH AMERICA: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 136
TABLE 73 NORTH AMERICA: CONTRAST MEDIA MARKET, BY FORM,
2024–2031 (USD MILLION) 136
TABLE 74 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MODALITY,
2024–2031 (USD MILLION) 136
TABLE 75 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 137
TABLE 76 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE,
2024–2031 (USD MILLION) 137
TABLE 77 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION,
2024–2031 (USD MILLION) 138
TABLE 78 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 138
TABLE 79 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER,
2024–2031 (USD MILLION) 138
TABLE 80 US: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 81 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 140
TABLE 82 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 83 EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 141
TABLE 84 EUROPE: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 142
TABLE 85 EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 142
TABLE 86 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 142
TABLE 87 EUROPE: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE,
2024–2031 (USD MILLION) 143
TABLE 88 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 143
TABLE 89 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 143
TABLE 90 EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 144
TABLE 91 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 92 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 146
TABLE 93 UK: COUNT OF IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 147
TABLE 94 UK: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 147
TABLE 95 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 148
TABLE 96 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 149
TABLE 97 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 150
TABLE 98 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 99 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 152
TABLE 100 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 152
TABLE 101 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY,
2024–2031 (USD MILLION) 152
TABLE 102 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 153
TABLE 103 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE,
2024–2031 (USD MILLION) 153
TABLE 104 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 153
TABLE 105 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION,
2024–2031 (USD MILLION) 154
TABLE 106 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER,
2024–2031 (USD MILLION) 154
TABLE 107 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 155
TABLE 108 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 109 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 157
TABLE 110 HIGH CANCER BURDEN AND STRONG HEALTHCARE SPENDING –
KEY DEMAND DRIVERS 157
TABLE 111 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 112 SOUTH KOREA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 159
TABLE 113 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 160
TABLE 114 LATIN AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 115 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 116 LATIN AMERICA: CONTRAST MEDIA MARKET, BY FORM,
2024–2031 (USD MILLION) 161
TABLE 117 LATIN AMERICA: CONTRAST MEDIA MARKET, BY MODALITY,
2024–2031 (USD MILLION) 162
TABLE 118 LATIN AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF
ADMINISTRATION, 2024–2031 (USD MILLION) 162
TABLE 119 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE,
2024–2031 (USD MILLION) 162
TABLE 120 LATIN AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 163
TABLE 121 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INDICATION,
2024–2031 (USD MILLION) 163
TABLE 122 LATIN AMERICA: CONTRAST MEDIA MARKET, BY END USER,
2024–2031 (USD MILLION) 163
TABLE 123 BRAZIL: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 124 MEXICO: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 125 REST OF LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 166
TABLE 126 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 127 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 167
TABLE 128 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY FORM,
2024–2031 (USD MILLION) 168
TABLE 129 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY MODALITY,
2024–2031 (USD MILLION) 168
TABLE 130 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 169
TABLE 131 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 169
TABLE 132 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 169
TABLE 133 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INDICATION,
2024–2031 (USD MILLION) 170
TABLE 134 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY END USER,
2024–2031 (USD MILLION) 170
TABLE 135 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 171
TABLE 136 REST OF MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 172
TABLE 137 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CONTRAST MEDIA MARKET, 2022–2025 174
TABLE 138 CONTRAST MEDIA MARKET: DEGREE OF COMPETITION 177
TABLE 139 CONTRAST MEDIA MARKET: REGION FOOTPRINT 185
TABLE 140 CONTRAST MEDIA MARKET: PRODUCT TYPE FOOTPRINT 186
TABLE 141 CONTRAST MEDIA MARKET: MODALITY FOOTPRINT 187
TABLE 142 CONTRAST MEDIA MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 188
TABLE 143 CONTRAST MEDIA MARKET: INDICATION FOOTPRINT 189
TABLE 144 CONTRAST MEDIA MARKET: END USER FOOTPRINT 190
TABLE 145 CONTRAST MEDIA MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SME PLAYERS, BY PRODUCT TYPE, AND REGION 194
TABLE 146 CONTRAST MEDIA MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 195
TABLE 147 CONTRAST MEDIA MARKET: DEALS, JANUARY 2023–JUNE 2026 196
TABLE 148 CONTRAST MEDIA MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026 196
TABLE 149 GE HEALTHCARE: COMPANY OVERVIEW 197
TABLE 150 GE HEALTHCARE: PRODUCTS OFFERED 199
TABLE 151 GE HEALTHCARE: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 199
TABLE 152 BRACCO IMAGING: COMPANY OVERVIEW 201
TABLE 153 BRACCO IMAGING: PRODUCTS OFFERED 201
TABLE 154 BRACCO IMAGING: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 203
TABLE 155 BRACCO IMAGING: DEALS, JANUARY 2023–JANUARY 2026 203
TABLE 156 BAYER AG: COMPANY OVERVIEW 205
TABLE 157 BAYER AG: PRODUCTS OFFERED 206
TABLE 158 BAYER AG: EXPANSIONS, JANUARY 2023–JANUARY 2026 207
TABLE 159 GUERBET : COMPANY OVERVIEW 209
TABLE 160 GUERBET: PRODUCTS OFFERED 210
TABLE 161 GUERBET : PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 211
TABLE 162 LANTHEUS HOLDINGS, INC.: COMPANY OVERVIEW 213
TABLE 163 LANTHEUS HOLDINGS, INC.: PRODUCTS OFFERED 214
TABLE 164 UNIJULES LIFE SCIENCES LTD.: COMPANY OVERVIEW 216
TABLE 165 UNIJULES LIFE SCIENCES LTD. PRODUCTS OFFERED 217
TABLE 166 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 218
TABLE 167 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 219
TABLE 168 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW 221
TABLE 169 SANOCHEMIA PHARMAZEUTIKA GMBH : PRODUCTS OFFERED 222
TABLE 170 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW 223
TABLE 171 TAEJOON PHARM CO., LTD: PRODUCTS OFFERED 223
TABLE 172 JODAS EXPOIM: BUSINESS OVERVIEW 224
TABLE 173 JODAS EXPOIM : PRODUCTS OFFERED 225
TABLE 174 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW 226
TABLE 175 IMAX DIAGNOSTIC IMAGING LIMITED : PRODUCTS OFFERED 226
TABLE 176 IMAX DIAGNOSTIC IMAGING LIMITED : PIPELINE PRODUCTS 227
TABLE 177 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW 228
TABLE 178 YANGTZE RIVER PHARMACEUTICAL GROUP: PIPELINE PRODUCTS 229
TABLE 179 LIVEALTH: BUSINESS OVERVIEW 230
TABLE 180 LIVEALTH: PRODUCTS OFFERED 230
TABLE 181 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW 232
TABLE 182 BEIJING BEILU PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 232
TABLE 183 BEIJING BEILU PHARMACEUTICAL CO., LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–JANUARY 2026 233
TABLE 184 ARCO LIFESCIENCES (I) PVT. LTD.: COMPANY OVERVIEW 235
TABLE 185 STANEX DRUGS & CHEMICALS PVT. LTD.: COMPANY OVERVIEW 236
TABLE 186 ONKO ILAC SAN. VE TIC. A.S.: COMPANY OVERVIEW 237
TABLE 187 FRESENIUS KABI: COMPANY OVERVIEW 238
TABLE 188 BIEM ILAC SAN. VE: COMPANY OVERVIEW 239
TABLE 189 ADVACARE PHARMA: COMPANY OVERVIEW 240
TABLE 190 FUJIFILM WAKO CHEMICAL CORPORATION: COMPANY OVERVIEW 241
TABLE 191 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 242
TABLE 192 NANOPET PHARMA GMBH: COMPANY OVERVIEW 243
TABLE 193 CONTRAST MEDIA MARKET: RESEARCH ASSUMPTIONS 256

LIST OF FIGURES

FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION AND REGIONAL SCOPE 25
FIGURE 2 MARKET SCENARIO 30
FIGURE 3 GLOBAL CONTRAST MEDIA MARKET, 2023–2031 30
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST
MEDIA MARKET, 2020–2025 31
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CONTRAST MEDIA MARKET 32
FIGURE 6 HIGH-GROWTH SEGMENTS IN CONTRAST MEDIA MARKET, 2025–2031 33
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CONTRAST MEDIA MARKET DURING FORECAST PERIOD 33
FIGURE 8 CONTRAST MEDIA MARKET DRIVEN BY RISING IMAGING VOLUMES, LOW-DOSE INNOVATIONS, AND EXPANDING ADOPTION ACROSS KEY REGIONS 35
FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE 36
FIGURE 10 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS
ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 37
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031 38
FIGURE 12 CONTRAST AGENT MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 39
FIGURE 13 CONTRAST MEDIA MARKET: PORTER’S FIVE FORCES ANALYSIS 50
FIGURE 14 CONTRAST MEDIA MARKET: SUPPLY CHAIN ANALYSIS 55
FIGURE 15 CONTRAST MEDIA MARKET: ECOSYSTEM ANALYSIS 56
FIGURE 16 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS, BY REGION, 2026–2024 (USD) 58
FIGURE 17 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER 60
FIGURE 18 CONTRAST MEDIA MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMER BUSINESS 63
FIGURE 19 CONTRAST MEDIA MARKET: FUNDING SCENARIO, 2019–2023 (USD MILLION) 64
FIGURE 20 NUMBER OF DEALS IN CONTRAST MEDIA MARKET, BY KEY PLAYER, 2019–2023 64
FIGURE 21 VALUE OF DEALS IN CONTRAST MEDIA MARKET, BY KEY PLAYER,
2019–2023 (USD) 65
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR CONTRAST MEDIA MARKET, BY PRODUCT 70
FIGURE 23 KEY BUYING CRITERIA FOR END USERS 71
FIGURE 24 CONTRAST MEDIA MARKET: UNMET NEED ANALYSIS 75
FIGURE 25 PATENT ANALYSIS FOR CONTRAST MEDIA MARKET,
JANUARY 2015–DECEMBER 2025 78
FIGURE 26 KEY AI USE CASES IN CONTRAST MEDIA ECOSYSTEM 81
FIGURE 27 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT 135
FIGURE 28 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT 151
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET,
2021–2025 (USD MILLION) 176
FIGURE 30 CONTRAST MEDIA MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 177
FIGURE 31 RANKING OF KEY PLAYERS IN CONTRAST MEDIA MARKET (2024) 179
FIGURE 32 EV/EBITDA OF TOP PLAYERS (2026) 179
FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP PLAYERS (2026) 180
FIGURE 34 CONTRAST MEDIA MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 181
FIGURE 35 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 183
FIGURE 36 CONTRAST MEDIA MARKET: COMPANY FOOTPRINT 184
FIGURE 37 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 192
FIGURE 38 GE HEALTHCARE: COMPANY SNAPSHOT (2025) 198
FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2025) 206
FIGURE 40 GUERBET: COMPANY SNAPSHOT (2025) 210
FIGURE 41 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2025) 214
FIGURE 42 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 219
FIGURE 43 CONTRAST MEDIA MARKET: RESEARCH DATA 244
FIGURE 44 CONTRAST MEDIA MARKET: RESEARCH DESIGN 245
FIGURE 45 PRIMARY SOURCES 248
FIGURE 46 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 249
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 250
FIGURE 48 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 251
FIGURE 49 CONTRAST MEDIA MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 252
FIGURE 50 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 253
FIGURE 51 DATA TRIANGULATION 255

---

---